R. M. Alden Research Laboratory, Santa Monica, California 90404, 1 and David Geffen School of Medicine at UCLA, Los Angeles, California
|
|
- Avis Phelps
- 6 years ago
- Views:
Transcription
1 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2006, p Vol. 50, No /06/$ doi: /aac Copyright 2006, American Society for Microbiology. All Rights Reserved. In Vitro Activities of Dalbavancin and 12 Other Agents against 329 Aerobic and Anaerobic Gram-Positive Isolates Recovered from Diabetic Foot Infections Ellie J. C. Goldstein, 1,2 * Diane M. Citron, 1 Yumi A. Warren, 1 Kerin L. Tyrrell, 1 C. Vreni Merriam, 1 and Helen T. Fernandez 1 R. M. Alden Research Laboratory, Santa Monica, California 90404, 1 and David Geffen School of Medicine at UCLA, Los Angeles, California Received 6 March 2006/Returned for modification 5 April 2006/Accepted 3 May 2006 Tests of dalbavancin s in vitro activity against 209 aerobic and 120 anaerobic isolates from pretreatment diabetic foot infections showed an MIC 90 of <0.125 g/ml against methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant S. aureus (MRSA), and 120 anaerobes (Clostridium perfringens, other clostridia, Peptoniphilus asaccharolyticus, Finegoldia magna, and Anaerococcus prevotii), compared to respective MIC 90 s for MSSA and MRSA of 0.5 and 1 g/ml for vancomycin, 4 and 4 g/ml for linezolid, 0.5 and 0.5 g/ml for daptomycin, and 0.25 and >8 g/ml for clindamycin. Diabetes will affect 14.5 million Americans by 2010 (8), and diabetic foot infections (DFIs) account for 20% of all hospitalizations of diabetic patients (1). DFIs are often multibacterial with aerobic and anaerobic bacteria. Recently, community-acquired methicillin-resistant Staphylococcus aureus (MRSA) (2, 3, 14) has accounted for 50% of all S. aureus skin and skin structure infection (SSTI) isolates (2, 3, 14). Previously, we noted (6) that MRSA was isolated from 20% of DFIs. As a reference lab for a DFI study, we received 473 pretreatment specimens, of which 91.3% grew aerobic bacteria, including 48% that grew S. aureus as one of the isolates (one-quarter of which were MRSA), and 41.6% grew anaerobes, with anaerobic gram-positive cocci the most common isolates. Dalbavancin (BI397) is new glycopeptide (4, 10) with good activity against gram-positive organisms, including MRSA, but none against gram-negative organisms (13, 19). Dalbavancin has a long elimination half-life ( 8.5 days) and has been effective in treating gram-positive SSTIs (9, 18) with a two-dose regimen. For DFIs, an antimicrobial agent with a long half-life, especially one administered once weekly, seems to be advantageous. Specimens were obtained from patients with clinical infection who had not received antimicrobials within 48 h and after wound debridement. To avoid bias, 329 consecutively isolated gram-positive aerobic and anaerobic organisms were selected for this study. Isolates were identified by standard criteria (12, 15) and stored in skim milk at 70 C. Frozen anaerobic cultures were subcultured twice onto brucella agar supplemented with hemin, vitamin K 1, and 5% sheep blood (Anaerobe Systems, Morgan Hill, CA) to ensure purity and good growth. Aerobic strains were subcultured to Trypticase soy blood agar. Susceptibility testing was performed according to CLSI (formerly NCCLS) standards M11-A6 (17) and M7-A6 (16). * Corresponding author. Mailing address: Alden Research Laboratory, 2021 Santa Monica Blvd., no. 740 East, Santa Monica, CA Phone: (310) Fax: (310) ejcgmd@aol.com. The types and numbers of strains tested are shown in Table 1. Laboratory-standard reference powders were either obtained from their manufacturers or purchased from Sigma Chemicals (St. Louis, MO). The MICs for anaerobes were determined by the agar dilution method using brucella agar supplemented with hemin, vitamin K 1, and 5% laked sheep blood. Antimicrobial agents were reconstituted according to the manufacturers instructions. Serial twofold dilutions of dalbavancin were prepared at 100-fold the final concentration in dimethyl sulfoxide on the day of the test and added to the agar medium at a dilution of 1:100. The other antimicrobial agents were diluted and added according to the CLSI procedure (17). The agar plates were inoculated with a Steers replicator (Craft Machine Inc., Chester, PA) with an inoculum of 10 5 CFU/spot, incubated in an anaerobic chamber (Anaerobe Systems) at 37 C for 44 to 48 h, and then examined. Control strains (Bacteroides fragilis ATCC 25285, the newly proposed Clostridium difficile ATCC 70057, and S. aureus ATCC 29213) were tested simultaneously. Aerobic organisms were tested by the broth microdilution method using cation-adjusted Mueller-Hinton broth, with 2.5% lysed horse blood supplementation for the streptococci and corynebacteria. Dalbavancin was tested separately in dryformat trays prepared by TREK Diagnostics (Cleveland, OH) and provided by Vicuron (now Pfizer, Inc., New York, NY). The trays containing the remaining antimicrobials were prepared in house with serial twofold dilutions of test drugs using the Quick-Spense apparatus (Sandy Springs Instrument Co., Germantown, MD). Daptomycin tests were supplemented with additional Ca 2 to 50 mg/liter. The trays were stored at 70 C until used. Enterococcus faecalis ATCC and S. aureus ATCC were tested simultaneously. The in vitro activities of dalbavancin and 12 comparator agents are shown in Table 1. Dalbavancin had an MIC 90 of g/ml against methicillin-susceptible S. aureus (MSSA) and MRSA isolates. Other MIC 90 s for MSSA and MRSA, respectively, were 0.5 and 1 g/ml for vancomycin, 4 and 4 g/ml for linezolid, 0.5 and 0.5 g/ml for daptomycin, and 2875
2 2876 NOTES ANTIMICROB. AGENTS CHEMOTHER. TABLE 1. In vitro activities of dalbavancin and 12 comparator antimicrobial agents against 209 aerobic and 120 anaerobic gram-positive organisms Aerobes MSSA (43) Dalbavancin Vancomycin Linezolid Daptomycin Meropenem Imipenem Piperacillin-tazobactam Penicillin Amoxicillin-clavulanate Levofloxacin Clindamycin Cefotetan Oxacillin MRSA (60) Dalbavancin Vancomycin Linezolid Daptomycin Meropenem Imipenem Piperacillin-tazobactam Penicillin Amoxicillin-clavulanate Levofloxacin Clindamycin Cefotetan Oxacillin Staphylococcus spp., coagulase-negative (20) a Dalbavancin Vancomycin Linezolid Daptomycin Meropenem Imipenem Piperacillin-tazobactam Penicillin Amoxicillin-clavulanate Levofloxacin Clindamycin Cefotetan Oxacillin Streptococcus agalactiae (24) Dalbavancin Linezolid Daptomycin Meropenem Imipenem Piperacillin-tazobactam Penicillin Amoxicillin-clavulanate Levofloxacin Clindamycin Cefotetan Beta-hemolytic Streptococcus spp., other (22) b Dalbavancin Vancomycin Linezolid Daptomycin Continued on following page
3 VOL. 50, 2006 NOTES 2877 TABLE 1 Continued Meropenem Imipenem Piperacillin-tazobactam Penicillin Amoxicillin-clavulanate Levofloxacin Clindamycin Cefotetan Corynebacterium amycolatum (20) Dalbavancin Linezolid Daptomycin Meropenem Imipenem Piperacillin-tazobactam Penicillin Amoxicillin-clavulanate Levofloxacin Clindamycin Cefotetan Corynebacterium spp. (20) c Dalbavancin Linezolid Daptomycin Meropenem Imipenem Piperacillin-tazobactam Penicillin Amoxicillin-clavulanate Levofloxacin Clindamycin Cefotetan Anaerobes Clostridium spp. (20) d Dalbavancin Vancomycin Daptomycin Linezolid Imipenem Meropenem Amoxicillin-clavulanate Penicillin Piperacillin-tazobactam Cefotetan Levofloxacin Clindamycin Metronidazole Peptoniphilus asaccharolyticus (20) Dalbavancin Vancomycin Daptomycin Imipenem Meropenem Amoxicillin-clavulanate Penicillin Piperacillin-tazobactam Cefotetan Levofloxacin Continued on following page
4 2878 NOTES ANTIMICROB. AGENTS CHEMOTHER. TABLE 1 Continued Clindamycin Metronidazole Finegoldia magna (29) Dalbavancin Vancomycin Daptomycin Linezolid Imipenem Meropenem Amoxicillin-clavulanate Penicillin Piperacillin-tazobactam Cefotetan Levofloxacin Clindamycin Metronidazole Anaerococcus prevotii (20) Dalbavancin Vancomycin Daptomycin Imipenem Meropenem Amoxicillin-clavulanate Penicillin Piperacillin-tazobactam Cefotetan Levofloxacin Clindamycin Metronidazole Other anaerobic gram-positive cocci (31) e Dalbavancin Vancomycin Daptomycin Imipenem Meropenem Amoxicillin-clavulanate Penicillin Piperacillin-tazobactam Cefotetan Levofloxacin Clindamycin Metronidazole a Staphylococcus epidermidis (4), S. haemolyticus (3), S. capitis (1), S. caprae (1), S. cohnii (1), S. hominis (1), S. lugdunensis (3), S. schleiferi (1), S. sciuri (2), S. simulans (2), and S. warneri (1). b Streptococcus group G (19) and S. pyogenes (3). c Corynebacterium group F-1 (1), C. glucuronolyticum (1), C. jeikeium (10), C. simulans (1), C. striatum (5), C. urealyticum (1), and Corynebacterium sp. (1). d Clostridium cadaveris (4), C. clostridioforme (3), C. innocuum (1), C. perfringens (10), C. sphenoides (1), and C. subterminale (1). e Peptostreptococcus anaerobius (9), Peptoniphilus harei (4), P. vaginalis (7), Micromonas micros (7), and Anaerococcus tetradius (4) and 8 g/ml for clindamycin. The MIC of dalbavancin for one of three strains of Staphylococcus haemolyticus was 2 g/ml. To determine if this was peculiar to the species, we tested 16 additional strains and found the range to be 0.06 to g/ml. Against Streptococcus agalactiae, Streptococcus pyogenes, and group G beta-hemolytic streptococci, dalbavancin had an MIC 90 of g/ml. Dalbavancin inhibited Corynebacterium amycolatum and Corynebacterium jeikeium strains at 1 g/ml and was active against 120 anaerobes (Clostridium perfringens, other clostridia, Peptoniphilus asaccharolyticus, Finegoldia magna, Anaerococcus prevotii, and other anaerobic gram-positive cocci), with MIC 90 sof g/ml. Dalbavancin was generally at least twofold more active than vancomycin and daptomycin and fourfold more active than linezolid against MRSA, MSSA, and coagulase-negative staphylococcus isolates. Most ( 50%) of the MRSA isolates were resistant to clindamycin (MICs of 8 g/ml). In vitro studies on dalbavancin have focused on aerobic gram-positive isolates that come from a variety of clinical
5 VOL. 50, 2006 NOTES 2879 sources, including thousands of European and American staphylococcal isolates (11, 13, 19). MIC 90 s for S. aureus and coagulase-negative isolates, whether susceptible or resistant to methicillin, were in most cases 0.06 g/ml; somewhat lower MICs were observed for streptococci. Higher MICs were seen only with some vancomycin-resistant E. faecalis and E. faecium strains. Goldstein et al. (5) studied 238 anaerobes and 52 Corynebacterium species and noted that dalbavancin was 1 to 3 dilutions more active than vancomycin against most strains. Recent studies (7; D. M. Citron, E. J. C. Goldstein, B. A. Lipsky, A. Tice, D. E. Morgenstern, and M. A. Abramson, 45th Intersci. Conf. Antimicrob. Agents Chemother., abstr. E-1440, 2005) have suggested that the source of isolates may be an important factor that influences the activity of agents, noting different susceptibilities of anaerobic gram-positive cocci isolated from DFIs compared to those from intra-abdominal infections. Our study is unique in that it examined only strains isolated from pretreatment DFIs. We found that dalbavancin was more active against MSSA and MRSA isolates than vancomycin, linezolid, daptomycin, and clindamycin and was active against C. perfringens, other clostridia, P. asaccharolyticus, F. magna, and A. prevotii, with MIC 90 sof g/ml. In a recent clinical comparison, dalbavancin ( 90% clinical success rate) was equivalent to linezolid in the treatment of complicated SSTIs (9) with MRSA as a baseline pathogen in 51% of patients, 23% of whom were diabetic. The bacteriology of the DFIs was not specifically elucidated. Our study showed dalbavancin to have excellent in vitro activity against the 329 gram-positive aerobic and anaerobic DFI strains tested. The in vitro data coupled with the clinical studies suggest that dalbavancin is active against a wide variety of gram-positive isolates and might provide an advantage for patient management of DFI in emergency departments, as well as both outpatient and inpatient settings. This study was sponsored in part by a grant from Vicuron Pharmaceuticals Inc. We thank Judee H. Knight and Alice E. Goldstein for various forms of assistance. REFERENCES 1. Bailey, T. S., H. M. Yu, and E. J. Rayfield Patterns of foot examination in a diabetes clinic. Am. J. Med. 78: Diederen, B. M., and J. A. Kluytmans The emergence of infections with community-associated methicillin resistant Staphylococcus aureus. J.Infect. 52: Frazee, B. W., J. Lynn, E. D. Charlebois, L. Lambert, D. Lowery, and F. Perdreau-Remington High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections. Ann. Emerg. Med. 45: Goldstein, B. P., G. Candiani, T. M. Arain, G. Romano, I. Ciciliato, M. Berti, M. Abbondi, R. Scotti, M. Mainini, and F. Ripamonti Antimicrobial activity of MDL 63,246, a new semisynthetic glycopeptide antibiotic. Antimicrob. Agents Chemother. 39: Goldstein, E. J. C., D. M. Citron, C. V. Merriam, Y. Warren, K. Tyrrell, and H. T. Fernandez In vitro activities of dalbavancin and nine comparator agents against anaerobic gram-positive species and corynebacteria. Antimicrob. Agents Chemother. 47: Goldstein, E. J. C., D. M. Citron, and C. A. Nesbit Diabetic foot infections. Bacteriology and activity of 10 oral antimicrobial agents against bacteria isolated from consecutive cases. Diabetes Care 19: Goldstein, E. J. C., D. M. Citron, Y. A. Warren, K. L. Tyrrell, C. V. Merriam, and H. Fernandez In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections. Antimicrob. Agents Chemother. 50: Hogan, P., T. Dall, and P. Nikolov Economic costs of diabetes in the US in Diabetes Care 26: Jauregui, L. E., S. Babazadeh, E. Seltzer, L. Goldberg, D. Krievins, M. Frederick, D. Krause, I. Satilovs, Z. Endzinas, J. Breaux, and W. O Riordan Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin. Infect. Dis. 41: Jones, R. N., D. J. Biedenbach, D. M. Johnson, and M. A. Pfaller In vitro evaluation of BI 397, a novel glycopeptide antimicrobial agent. J. Chemother. 13: Jones, R. N., M. S. Stillwell, H. S. Sader, T. R. Fritsche, and B. P. Goldstein Spectrum and potency of dalbavancin tested against 3322 gram-positive cocci isolated in the United States Surveillance Program (2004). Diagn. Microbiol. Infect. Dis. 54: Jousimies-Somer, H. R., P. Summanen, D. M. Citron, E. J. Baron, H. M. Wexler, and S. M. Finegold Wadsworth-KTL anaerobic bacteriology manual. Star Publishing, Belmont, CA. 13. Lin, G., K. Credito, L. M. Ednie, and P. C. Appelbaum Antistaphylococcal activity of dalbavancin, an experimental glycopeptide. Antimicrob. Agents Chemother. 49: Moran, G. J., R. N. Amii, F. M. Abrahamian, and D. A. Talan Methicillin-resistant Staphylococcus aureus in community-acquired skin infections. Emerg. Infect. Dis. 11: Murray, P. R., E. J. Baron, J. H. Jorgensen, M. A. Pfaller, and R. H. Yolken (ed.) Manual of clinical microbiology, 8th ed. ASM Press, Washington, D.C. 16. NCCLS Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Document M7-A6. NCCLS, Wayne, Pa. 17. NCCLS Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard M11-A6. NCCLS, Wayne, Pa. 18. Seltzer, E., M. B. Dorr, B. P. Goldstein, M. Perry, J. A. Dowell, and T. Henkel Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin. Infect. Dis. 37: Streit, J. M., T. R. Fritsche, H. S. Sader, and R. N. Jones Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn. Microbiol. Infect. Dis. 48:
AAC Revised. Activity of a Novel Cyclic Lipopeptide, CB-183,315 Against Resistant Clostridium difficile
AAC Accepts, published online ahead of print on 5 March 2012 Antimicrob. Agents Chemother. doi:10.1128/aac.06257-11 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 AAC06257-11
More informationANTI-ANAEROBIC ACTIVITIES OF SULOPENEM COMPARED TO SIX OTHER. Departments of Pathology, Hershey Medical Center, Hershey, PA 17033
AAC Accepts, published online ahead of print on 17 February 2009 Antimicrob. Agents Chemother. doi:10.1128/aac.01557-08 Copyright 2009, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationSESSION XVI NEW ANTIBIOTICS
SESSION XVI NEW ANTIBIOTICS New Antibiotics to Treat Anaerobic Infections 2 Goldstein, E.J.C.;* Citron, D.M. Antibiotic Pharmacodynamics 3 Stein, G.E.* Targeting Selenium Metabolism in Stickland Fermentors:
More informationTel: Fax:
CONCISE COMMUNICATION Bactericidal activity and synergy studies of BAL,a novel pyrrolidinone--ylidenemethyl cephem,tested against streptococci, enterococci and methicillin-resistant staphylococci L. M.
More informationagainst Clinical Isolates of Gram-Positive Bacteria
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 366-370 Vol. 37, No. 0066-0/93/00366-05$0.00/0 Copyright 993, American Society for Microbiology In Vitro Activity of CP-99,9, a New Fluoroquinolone,
More informationDalbavancin, enterococci, Gram-positive cocci, Latin America, staphylococci, streptococci
ORIGINAL ARTICLE 10.1111/j.1469-0691.2004.01051.x Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres A. C. Gales 1, H. S. Sader 1,2
More informationIn vitro activity of telavancin against recent Gram-positive clinical isolates: results of the Prospective European Surveillance Initiative
Journal of Antimicrobial Chemotherapy (2008) 62, 116 121 doi:10.1093/jac/dkn124 Advance Access publication 19 April 2008 In vitro activity of telavancin against recent Gram-positive clinical isolates:
More informationCiprofloxacin, Enoxacin, and Ofloxacin against Aerobic and
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 1988, p. 1143-1148 Vol., No. 8 0066-4804/88/081143-06$00/0 Copyright 1988, American Society for Microbiology Comparative Activities of, Amoxicillin-Clavulanic
More informationAntimicrobial Susceptibility of Clinically Relevant Gram-Positive Anaerobic Cocci Collected over a Three-Year Period in the Netherlands
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 2011, p. 1199 1203 Vol. 55, No. 3 0066-4804/11/$12.00 doi:10.1128/aac.01771-09 Copyright 2011, American Society for Microbiology. All Rights Reserved. Antimicrobial
More informationon February 12, 2018 by guest
AAC Accepted Manuscript Posted Online 12 February 2018 Antimicrob. Agents Chemother. doi:10.1128/aac.00047-18 Copyright 2018 Stapert et al. This is an open-access article distributed under the terms of
More informationMICHAEL J. RYBAK,* ELLIE HERSHBERGER, TABITHA MOLDOVAN, AND RICHARD G. GRUCZ
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2000, p. 1062 1066 Vol. 44, No. 4 0066-4804/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. In Vitro Activities of Daptomycin,
More informationReceived 5 February 2004/Returned for modification 16 March 2004/Accepted 7 April 2004
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2004, p. 3112 3118 Vol. 48, No. 8 0066-4804/04/$08.00 0 DOI: 10.1128/AAC.48.8.3112 3118.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.
More informationAntibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting
Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria
More informationActivity of Linezolid Tested Against Uncommonly Isolated Gram-positive ACCEPTED
AAC Accepts, published online ahead of print on 8 January 2007 Antimicrob. Agents Chemother. doi:10.1128/aac.01496-06 Copyright 2007, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationAntibiotic Abyss. Discussion Points. MRSA Treatment Guidelines
Antibiotic Abyss Fredrick M. Abrahamian, D.O., FACEP, FIDSA Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical Center Sylmar, California
More informationEffect of dalbavancin on the normal intestinal microflora
Journal of Antimicrobial Chemotherapy (00), 1 doi:10.109/jac/dkl1 Advance Access publication 1 July 00 Effect of dalbavancin on the normal intestinal microflora Carl Erik Nord*, Gundars Rasmanis and Elisabeth
More information2 0 hr. 2 hr. 4 hr. 8 hr. 10 hr. 12 hr.14 hr. 16 hr. 18 hr. 20 hr. 22 hr. 24 hr. (time)
Key words I μ μ μ μ μ μ μ μ μ μ μ μ μ μ II Fig. 1. Microdilution plate. The dilution step of the antimicrobial agent is prepared in the -well microplate. Serial twofold dilution were prepared according
More informationHelp with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST
Help with moving disc diffusion methods from BSAC to EUCAST This document sets out the main differences between the BSAC and EUCAST disc diffusion methods with specific emphasis on preparation prior to
More informationIn Vitro Antimicrobial Activity of CP-99,219, a Novel Azabicyclo-Naphthyridone
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 39-353 0066-0/93/0039-05$0.00/0 Copyright 993, American Society for Microbiology Vol. 37, No. In Vitro Antimicrobial Activity of, a Novel Azabicyclo-Naphthyridone
More informationScottish Medicines Consortium
Scottish Medicines Consortium daptomycin 350mg powder for concentrate for solution for infusion (Cubicin ) Chiron Corporation Limited No. (248/06) 10 March 2006 The Scottish Medicines Consortium (SMC)
More informationEllie JC Goldstein Diane M. Citron C. Vreni Merriam Kerin L Tyrrell
AAC Accepts, published online ahead of print on 1 October 2012 Antimicrob. Agents Chemother. doi:10.1128/aac.01794-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 1 2 3 4 5
More informationMoxifloxacin resistance is prevalent among Bacteroides and Prevotella species in Greece
Journal of Antimicrobial Chemotherapy (2008) 62, 137 141 doi:10.1093/jac/dkn134 Advance Access publication 1 April 2008 Moxifloxacin resistance is prevalent among Bacteroides and Prevotella species in
More informationChildrens Hospital Antibiogram for 2012 (Based on data from 2011)
Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical
More informationINFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER
INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER University of Minnesota Health University of Minnesota Medical Center University of Minnesota Masonic Children s Hospital May 2017 Printed herein are
More information2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2017 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More informationGeneral Approach to Infectious Diseases
General Approach to Infectious Diseases 2 The pharmacotherapy of infectious diseases is unique. To treat most diseases with drugs, we give drugs that have some desired pharmacologic action at some receptor
More informationEvaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals
J Vet Diagn Invest :164 168 (1998) Evaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals Susannah K. Hubert, Phouc Dinh Nguyen, Robert D. Walker Abstract.
More informationMICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC
MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical
More information2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services
2015 Antibiogram Red Deer Regional Hospital Central Zone Alberta Health Services Introduction. This antibiogram is a cumulative report of the antimicrobial susceptibility rates of common microbial pathogens
More informationJanuary 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimum Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) Broth dilution: cation-adjusted Mueller-Hinton
More information2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2016 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More informationBBL CHROMagar MRSA Rev. 05 October 2008
I II III IV V VI VII BBL CHROMagar MRSA 8012632 Rev. 05 October 2008 QUALITY CONTROL PROCEDURES INTRODUCTION BBL CHROMagar MRSA, supplemented with chromogens and inhibitory agents, is used for the qualitative
More informationIn Vitro Activities of the Novel Cephalosporin LB against Multidrug-Resistant Staphylococci and Streptococci
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 2004, p. 53 62 Vol. 48, No. 1 0066-4804/04/$08.00 0 DOI: 10.1128/AAC.48.1.53 62.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.
More informationORIGINAL ARTICLE /j x
ORIGINAL ARTICLE 10.1111/j.1469-0691.2006.01550.x Antimicrobial susceptibility of Gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002 2004)
More informationIntrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
More informationIn vitro Activity Evaluation of Telavancin against a Contemporary Worldwide Collection of Staphylococcus. aureus. Rodrigo E. Mendes, Ph.D.
AAC Accepts, published online ahead of print on 12 April 2010 Antimicrob. Agents Chemother. doi:10.1128/aac.00301-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationACCEPTED. Anaerobe Reference Laboratory, Department of Bacterial and Inflammatory Diseases, National
AAC Accepts, published online ahead of print on April 00 Antimicrob. Agents Chemother. doi:./aac.000-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationAntibiotic Updates: Part II
Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01
More informationIn Vitro Evaluation of a Novel Ketolide Antimicrobial Agent, RU-64004
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 1997, p. 454 459 Vol. 41, No. 2 0066-4804/97/$04.00 0 Copyright 1997, American Society for Microbiology In Vitro Evaluation of a Novel Ketolide Antimicrobial
More informationMulticenter Study of In Vitro Susceptibility of the Bacteroides fragilis Group, 1995 to 1996, with Comparison of Resistance Trends from 1990 to 1996
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Oct. 1999, p. 2417 2422 Vol. 43, No. 10 0066-4804/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Multicenter Study of In Vitro
More information2015 Antibiotic Susceptibility Report
Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens
More informationUSA Product Label CLINTABS TABLETS. Virbac. brand of clindamycin hydrochloride tablets. ANADA # , Approved by FDA DESCRIPTION
VIRBAC CORPORATION USA Product Label http://www.vetdepot.com P.O. BOX 162059, FORT WORTH, TX, 76161 Telephone: 817-831-5030 Order Desk: 800-338-3659 Fax: 817-831-8327 Website: www.virbacvet.com CLINTABS
More informationMichael T. Sweeney* and Gary E. Zurenko. Infectious Diseases Biology, Pharmacia Corporation, Kalamazoo, Michigan 49007
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, June 2003, p. 1902 1906 Vol. 47, No. 6 0066-4804/03/$08.00 0 DOI: 10.1128/AAC.47.6.1902 1906.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationEpidemiology and Microbiology of Surgical Wound Infections
JOURNAL OF CLINICAL MICROBIOLOGY, Feb. 2000, p. 918 922 Vol. 38, No. 2 0095-1137/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. Epidemiology and Microbiology of Surgical
More informationTable 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities.
Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities. Gram-positive cocci: Staphylococcus aureus: *Resistance to penicillin is almost universal. Resistance
More informationAntibiotic Updates: Part I
Antibiotic Updates: Part I Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationEducating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges
Educating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges Janet Hindler, MCLS MT(ASCP) UCLA Medical Center jhindler@ucla.edu also working as a consultant with the Association
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The
More informationSurveillance of susceptibility patterns in 1297 European and US anaerobic and capnophilic isolates to co-amoxiclav and five other antimicrobial agents
Journal of Antimicrobial Chemotherapy (2004) 53, 1039 1044 DOI: 10.1093/jac/dkh248 Advance Access publication 5 May 2004 Surveillance of susceptibility patterns in 1297 European and US anaerobic and capnophilic
More informationOriginal Article. Suwanna Trakulsomboon, Ph.D., Visanu Thamlikitkul, M.D.
Original Article Vol. 25 No. 2 In vitro activity of daptomycin against MRSA:Trakulsomboon S & Thamlikitkul V. 57 In Vitro Activity of Daptomycin against Methicillin- Resistant Staphylococcus aureus (MRSA)
More informationEUCAST recommended strains for internal quality control
EUCAST recommended strains for internal quality control Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae ATCC 59 ATCC
More information2016 Antibiotic Susceptibility Report
Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates
More informationThe Basics: Using CLSI Antimicrobial Susceptibility Testing Standards
The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards Janet A. Hindler, MCLS, MT(ASCP) UCLA Health System Los Angeles, California, USA jhindler@ucla.edu 1 Learning Objectives Describe information
More informationUnderstanding the Hospital Antibiogram
Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital
More informationIn Vitro Activities of OPT-80 and Comparator Drugs against Intestinal Bacteria
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 2004, p. 4898 4902 Vol. 48, No. 12 0066-4804/04/$08.00 0 DOI: 10.1128/AAC.48.12.4898 4902.2004 Copyright 2004, American Society for Microbiology. All Rights
More informationMarc Decramer 3. Respiratory Division, University Hospitals Leuven, Leuven, Belgium
AAC Accepts, published online ahead of print on April 0 Antimicrob. Agents Chemother. doi:./aac.0001- Copyright 0, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationShould we test Clostridium difficile for antimicrobial resistance? by author
Should we test Clostridium difficile for antimicrobial resistance? Paola Mastrantonio Department of Infectious Diseases Istituto Superiore di Sanità, Rome,Italy Clostridium difficile infection (CDI) (first
More informationAberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015
Aberdeen Hospital Antibiotic Susceptibility Patterns For Commonly Isolated s For 2015 Services Laboratory Microbiology Department Aberdeen Hospital Nova Scotia Health Authority 835 East River Road New
More information56 Clinical and Laboratory Standards Institute. All rights reserved.
Table 2C 56 Clinical and Laboratory Standards Institute. All rights reserved. Table 2C. Zone Diameter and Minimal Inhibitory Concentration Breakpoints for Testing Conditions Medium: Inoculum: diffusion:
More informationEffects of Minocycline and Other Antibiotics on Fusobacterium necrophorum Infections in Mice
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 1975, p. 421-425 Copyright 0 1975 American Society for Microbiology Vol. 7, No. 4 Printed in U.S.A. Effects of Minocycline and Other s on Fusobacterium necrophorum
More informationSTAPHYLOCOCCI: KEY AST CHALLENGES
Romney Humphries, PhD D(ABMM) Section Chief, UCLA Clinical Microbiology Los Angeles CA rhumphries@mednet.ucla.edu STAPHYLOCOCCI: KEY AST CHALLENGES THE CHALLENGES detection of penicillin resistance detection
More informationANTIBIOTICS USED FOR RESISTACE BACTERIA. 1. Vancomicin
ANTIBIOTICS USED FOR RESISTACE BACTERIA 1. Vancomicin Vancomycin is used to treat infections caused by bacteria. It belongs to the family of medicines called antibiotics. Vancomycin works by killing bacteria
More informationConcise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
More informationMRSA. ( Staphylococcus aureus; S. aureus ) ( community-associated )
005 16 190-194 ( Staphylococcus aureus; S. aureus ) ( community-associated ) ( -susceptible Staphylococcus auerus; MSSA ) ( -resistant Staphylococcus auerus; ) ( ) ( -lactam ) ( glycopeptide ) ( Staphylococcus
More informationBACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016)
BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016) VA Palo Alto Health Care System April 14, 2017 Trisha Nakasone, PharmD, Pharmacy Service Russell Ryono, PharmD, Public Health Surveillance
More informationOriginal Article. Ratri Hortiwakul, M.Sc.*, Pantip Chayakul, M.D.*, Natnicha Ingviya, B.Sc.**
Original Article In Vitro Activity of Cefminox and Other β-lactam Antibiotics Against Clinical Isolates of Extended- Spectrum-β-lactamase-Producing Klebsiella pneumoniae and Escherichia coli Ratri Hortiwakul,
More informationEUCAST Workshop: Antimicrobial susceptibility testing with EUCAST breakpoints and methods
EUCAST Workshop: Antimicrobial susceptibility testing with EUCAST breakpoints and methods Susceptibility testing of infrequently isolated fastidious organisms Luis Martinez-Martínez Service of Microbiology
More informationOriginal Article. Hossein Khalili a*, Rasool Soltani b, Sorrosh Negahban c, Alireza Abdollahi d and Keirollah Gholami e.
Iranian Journal of Pharmaceutical Research (22), (2): 559-563 Received: January 2 Accepted: June 2 Copyright 22 by School of Pharmacy Shaheed Beheshti University of Medical Sciences and Health Services
More informationSuggestions for appropriate agents to include in routine antimicrobial susceptibility testing
Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory
More informationPresent Status of Therapy for Anaerobic Infections
89 Present Status of Therapy for Anaerobic Infections Sydney M. Finegold and Hannah M. Wexler From the Medical and Research Services, Veterans Affairs Medical Center West Los Angeles, and the Department
More informationBD BBL CHROMagar MRSA*
INSTRUCTIONS FOR USE READY-TO-USE PLATED MEDIA PA-257308.01 Rev.: Dec 2005 BD BBL CHROMagar MRSA* INTENDED USE BBL CHROMagar MRSA is a selective and differential medium for the qualitative direct detection
More informationThe prevalence of antibiotic resistance in anaerobic bacteria isolated from patients with skin infections Research Article
Gene Therapy and Molecular Biology Vol 9, page 263 Gene Ther Mol Biol Vol 9, 263-268, 2005 The prevalence of antibiotic resistance in anaerobic bacteria isolated from patients with skin infections Research
More informationPrinciples of Infectious Disease. Dr. Ezra Levy CSUHS PA Program
Principles of Infectious Disease Dr. Ezra Levy CSUHS PA Program I. Microbiology (1) morphology (e.g., cocci, bacilli) (2) growth characteristics (e.g., aerobic vs anaerobic) (3) other qualities (e.g.,
More informationComparison of BD BACTEC Plus Blood Culture Media versus VersaTREK REDOX
JCM Accepts, published online ahead of print on February 0 J. Clin. Microbiol. doi:./jcm.01- Copyright 0, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationBactiReg3 Event Notes Module Page(s) 4-9 (TUL) Page 1 of 21
www.wslhpt.org 2601 Agriculture Drive Madison, WI 53718 (800) 462-5261 (608) 265-1111 2015-BactiR Reg3 Shipment Date: September 14, 2015 Questions or comments should be directed to Amanda Weiss at 800-462-5261
More informationIn Vitro Susceptibility to Pexiganan of Bacteria Isolated from Infected Diabetic Foot Ulcers
In Vitro Susceptibility to Pexiganan of Bacteria Isolated from Infected Diabetic Foot Ulcers Yigong Ge, Dorothy MacDonald, Marietta M. Henry, Howard I. Hait, Kimberly A. Nelson, Benjamin A. Lipsky, Michael
More informationNecrotizing Soft Tissue Infections: Emerging Bacterial Resistance
Necrotizing Soft Tissue Infections: Emerging Bacterial Resistance Eileen M. Bulger, MD Professor of Surgery Harborview Medical Center University of Washington Objectives Review definition & diagnostic
More informationPerformance Information. Vet use only
Performance Information Vet use only Performance of plates read manually was measured in three sites. Each centre tested Enterobacteriaceae, streptococci, staphylococci and pseudomonas-like organisms.
More informationBacteriology of Moderate-to-Severe Diabetic Foot Infections and In Vitro Activity of Antimicrobial Agents
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 2007, p. 2819 2828 Vol. 45, No. 9 0095-1137/07/$08.00 0 doi:10.1128/jcm.00551-07 Copyright 2007, American Society for Microbiology. All Rights Reserved. Bacteriology
More informationEvaluation of MicroScan MIC Panels for Detection of
JOURNAL OF CLINICAL MICROBIOLOGY, May 1988, p. 816-820 Vol. 26, No. 5 0095-1137/88/050816-05$02.00/0 Copyright 1988, American Society for Microbiology Evaluation of MicroScan MIC Panels for Detection of
More informationOver 40 Posters/Abstracts in Support of TREK Presented at the 2004 ECCMID
Over 40 Posters/Abstracts in Support of TREK Presented at the ECCMID This was our best ECCMID ever for TREK presentations! The following posters and abstracts were in support of TREK products! Sensititre
More informationANTIMICROBIAL SUSCEPTIBILITY DETECTION OF ELEVATED MICs TO PENICILLINS IN β- HAEMOLYTIC STREPTOCOCCI
HAEMOLYTIC STREPTOCOCCI This specimen was designated as a sample from a skin wound that was to be cultured, identified to species level and susceptibility tested [1-3]. The culture contained a Streptococcus
More informationDetection of inducible clindamycin resistance among clinical isolates of Staphylococcus aureus in a tertiary care hospital
ISSN: 2319-7706 Volume 3 Number 9 (2014) pp. 689-694 http://www.ijcmas.com Original Research Article Detection of inducible clindamycin resistance among clinical isolates of Staphylococcus aureus in a
More informationQUICK REFERENCE. Pseudomonas aeruginosa. (Pseudomonas sp. Xantomonas maltophilia, Acinetobacter sp. & Flavomonas sp.)
Pseudomonas aeruginosa (Pseudomonas sp. Xantomonas maltophilia, Acinetobacter sp. & Flavomonas sp.) Description: Greenish gray colonies with some beta-hemolysis around each colony on blood agar (BAP),
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/26062
More informationLessons Learned from the Anaerobe Survey: Historical Perspective and Review of the Most Recent Data ( )
SUPPLEMENT ARTICLE Lessons Learned from the Anaerobe Survey: Historical Perspective and Review of the Most Recent Data (2005 2007) David R. Snydman, 1,2 Nilda V. Jacobus, 1 Laura A. McDermott, 1 Yoav Golan,
More informationMulticenter Study of Antimicrobial Susceptibility of Anaerobic Bacteria in Korea in 2012
Original Article Clinical Microbiology Ann Lab Med 2015;35:479-486 http://dx.doi.org/10.3343/alm.2015.35.5.479 ISSN 2234-3806 eissn 2234-3814 Multicenter Study of Antimicrobial Susceptibility of Anaerobic
More informationJasmine M. Chaitram, 1,2 * Laura A. Jevitt, 1,2 Sara Lary, 1,2 Fred C. Tenover, 1,2 and The WHO Antimicrobial Resistance Group 3,4
JOURNAL OF CLINICAL MICROBIOLOGY, June 2003, p. 2372 2377 Vol. 41, No. 6 0095-1137/03/$08.00 0 DOI: 10.1128/JCM.41.6.2372 2377.2003 The World Health Organization s External Quality Assurance System Proficiency
More informationThis article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and
This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution
More informationTHE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS
THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS Stefanie Desmet University Hospitals Leuven Laboratory medicine microbiology stefanie.desmet@uzleuven.be
More informationRESISTANCE OF STAPHYLOCOCCUS AUREUS TO VANCOMYCIN IN ZARQA, JORDAN
RESISTANCE OF STAPHYLOCOCCUS AUREUS TO VANCOMYCIN IN ZARQA, JORDAN Hussein Azzam Bataineh 1 ABSTRACT Background: Vancomycin has been widely used in the treatment of infections caused by Methicillin-Resistant
More informationClinical Policy: Clindamycin (Cleocin) Reference Number: CP.HNMC.08 Effective Date: Last Review Date: Line of Business: Medicaid - HNMC
Clinical Policy: (Cleocin) Reference Number: CP.HNMC.08 Effective Date: 07.01.17 Last Review Date: 02.18 Line of Business: Medicaid - HNMC Revision Log See Important Reminder at the end of this policy
More informationRoutine internal quality control as recommended by EUCAST Version 3.1, valid from
Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus
More informationOther Beta - lactam Antibiotics
Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics
More information2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine
2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose
More informationSynergism of penicillin or ampicillin combined with sissomicin or netilmicin against enterococci
Journal of Antimicrobial Chemotherapy (78) 4, 53-543 Synergism of penicillin or ampicillin combined with sissomicin or netilmicin against enterococci Chatrchal Watanakunakoni and Cheryl Glotzbecker Infectious
More informationThe β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018
The β- Lactam Antibiotics Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Penicillins. Cephalosporins. Carbapenems. Monobactams. The β- Lactam Antibiotics 2 3 How
More informationAn Approach to Linezolid and Vancomycin against Methicillin Resistant Staphylococcus Aureus
Article ID: WMC00590 ISSN 2046-1690 An Approach to Linezolid and Vancomycin against Methicillin Resistant Staphylococcus Aureus Author(s):Dr. K P Ranjan, Dr. D R Arora, Dr. Neelima Ranjan Corresponding
More informationResistance pattern of anaerobic bacteria isolated in a general hospital during a two-year period
Journal of Antimicrobial Chemotherapy (9), Supp. D, 9 6 Resistance pattern of anaerobic bacteria isolated in a general hospital during a two-year period J. F. Acar, F. W. Goldstein, M. D. Kitzis and M.
More information